

(51) International Patent Classification:
A61K 39/395 (2006.01)(21) International Application Number:
PCT/US2015/044396(22) International Filing Date:
8 August 2015 (08.08.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/035,336 8 August 2014 (08.08.2014) US
62/135,110 18 March 2015 (18.03.2015) US
62/135,122 18 March 2015 (18.03.2015) US(71) Applicant: **ALECTOR LLC** [US/US]; 953 Indiana Street,
San Francisco, CA 94107 (US).(72) Inventors: **MONROE, Kate**; c/o Alector LLC, 953 Indiana
Street, San Francisco, CA 94107 (US). **SCHWABE,
Tina**; c/o Alector LLC, 953 Indiana Street, San Francisco,
CA 94107 (US). **AVOGADRI-CONNORS, Francesca**;
c/o Alector LLC, 953 Indiana Street, San Francisco, CA94107 (US). **TASSI, Ilaria**; c/o Alector LLC, 953 Indiana
Street, San Francisco, CA 94107 (US). **LAM, Helen**; c/o
Alector LLC, 953 Indiana Street, San Francisco, CA 94107
(US). **ROSENTHAL, Arnon**; 150 Normandy Lane,
Woodside, CA 94062 (US).(74) Agents: **ZHOU, Jie** et al.; Morrison & Foerster LLP, 425
Market Street, San Francisco, CA 94105-2482 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

[Continued on next page]

(54) Title: ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF




FIG. 16

(57) Abstract: The invention is generally directed to methods and compositions that include antibodies, *e.g.*, monoclonal, chimeric, humanized antibodies, antibody fragments, *etc.*, that specifically bind a TREM2 protein, *e.g.*, a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.



TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

Published:

— *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:

28 July 2016